| Dr Vivek Khemka, MD | |
|
14200 W Celebrate Life Way, Goodyear, AZ 85338-3007 | |
| (623) 207-3000 | |
| Not Available |
| Full Name | Dr Vivek Khemka |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 14200 W Celebrate Life Way, Goodyear, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073792289 | NPI | - | NPPES |
| P00625102 | Other | AZ | RAILROAD MEDICARE |
| 356959 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 40642 (Arizona) | Primary |
| 207RX0202X | Internal Medicine - Medical Oncology | 40642 (Arizona) | Secondary |
| Entity Name | Honorhealth Ambulatory |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407050917 PECOS PAC ID: 5991603110 Enrollment ID: O20071005000449 |
News Archive
Treatment with a derivative of vitamin A called retinoic acid was associated with reduced lung cell growth in a group of former heavy smokers, according to a study published online October 30 in the Journal of the National Cancer Institute.
ASLAN Pharmaceuticals Pte Ltd and Array BioPharma Inc. today announced a license agreement to develop Array's HER2 / EGFR inhibitor, ARRY-543, currently entering Phase 2 development for solid tumors.
Great Basin Corporation, a privately-held life sciences company developing sample-to-result molecular diagnostic solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for its first molecular diagnostic test for Clostridium difficile.
ESMO announced the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.
› Verified 9 days ago
| Entity Name | Ctca Physicians Group Of Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609026806 PECOS PAC ID: 2264593474 Enrollment ID: O20081205000793 |
News Archive
Treatment with a derivative of vitamin A called retinoic acid was associated with reduced lung cell growth in a group of former heavy smokers, according to a study published online October 30 in the Journal of the National Cancer Institute.
ASLAN Pharmaceuticals Pte Ltd and Array BioPharma Inc. today announced a license agreement to develop Array's HER2 / EGFR inhibitor, ARRY-543, currently entering Phase 2 development for solid tumors.
Great Basin Corporation, a privately-held life sciences company developing sample-to-result molecular diagnostic solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for its first molecular diagnostic test for Clostridium difficile.
ESMO announced the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vivek Khemka, MD 14200 W Celebrate Life Way, Goodyear, AZ 85338-3007 Ph: () - | Dr Vivek Khemka, MD 14200 W Celebrate Life Way, Goodyear, AZ 85338-3007 Ph: (623) 207-3000 |
News Archive
Treatment with a derivative of vitamin A called retinoic acid was associated with reduced lung cell growth in a group of former heavy smokers, according to a study published online October 30 in the Journal of the National Cancer Institute.
ASLAN Pharmaceuticals Pte Ltd and Array BioPharma Inc. today announced a license agreement to develop Array's HER2 / EGFR inhibitor, ARRY-543, currently entering Phase 2 development for solid tumors.
Great Basin Corporation, a privately-held life sciences company developing sample-to-result molecular diagnostic solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for its first molecular diagnostic test for Clostridium difficile.
ESMO announced the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.
› Verified 9 days ago
Dr. Edward Markman, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1325 N Litchfield Rd Ste 110, Goodyear, AZ 85395 Phone: 623-935-9494 Fax: 623-935-9292 | |
Dr. Mark Edward Burnes, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 14940 West Indian School Road, Suite 400, Goodyear, AZ 85395 Phone: 623-935-3688 Fax: 888-628-9545 | |
William Nassour, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 13555 W Mcdowell Rd Ste 205, Goodyear, AZ 85395 Phone: 623-295-1190 Fax: 602-429-8595 | |
Comfort N. Ubadigbo, FNP-C Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1325 N Litchfield Rd Ste 110, Goodyear, AZ 85395 Phone: 623-935-9494 | |
Sanjay Saradhi Bommakanti, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 700 N Estrella Pkwy Ste 130, Goodyear, AZ 85338 Phone: 623-322-2144 Fax: 623-322-1165 | |
Paramvir Singh Sidhu, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 13555 W Mcdowell Rd, Suite 209, Goodyear, AZ 85395 Phone: 623-512-4310 Fax: 623-512-4311 |